Procter & Gamble(CH:PG)
CHF 137.98-0.94 (-0.68%)
CH:PG
Procter & Gamble stock drug pipeline
CHF 137.98
At close:-0.94 (-0.68%)
Procter & Gamble (PG) Drug Pipeline
7 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Stannous Fluoride Dentifrice, Sodium Fluoride Dentifrice, Electric Toothbrush, Cetylpyridinium Chloride (Cpc), Manual Toothbrush | Gingivitis | Phase IV | Completed | A Study is to Evaluate a Regimen on Gingivitis Using Traditional and Novel Assessment Methods | Sep 29, 2025 | ― |
| Sodium Monofluorophosphate Dentifrice, Stannous Fluoride Dentifrice, Test Stannous Fluoride Dentifrice | Gingivitis | Phase IV | Active Not Recruiting | Assessing Gingivitis and Plaque From a Marketed Toothpaste | Aug 28, 2025 | ― |
| 0.76% Sodium Monofluorophosphate Dentifrice, 0.454% Stannous Fluoride Dentifrice | Gingivitis | Phase I | Active Not Recruiting | Evaluating Gingivitis and Systemic Biomarkers | Apr 30, 2025 | ― |
| Sodium Monofluorophosphate Dentifrice, Stannous Fluoride Dentifrice, Sodium Fluoride Dentifrice | Gingivitis | Phase II | Completed | Assessing Gingivitis of 3 Different Dentifrices Compared to a Negative Control. | Mar 19, 2025 | ― |
| 0 Ppm F, 250 Ppm F As Mfp, 1100 Ppm As Mfp, 2800 Ppm F As Mfp | Caries | Phase I | Completed | Salivary Fluoride Clearance | Dec 11, 2024 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Stannous Fluoride Dentifrice, Sodium Fluoride Dentifrice, Electric Toothbrush, Cetylpyridinium Chloride (Cpc), Manual Toothbrush | Phase IV | Gingivitis | Completed | A Study is to Evaluate a Regimen on Gingivitis Using Traditional and Novel Assessment Methods | Sep 29, 2025 | ― |
| Sodium Monofluorophosphate Dentifrice, Stannous Fluoride Dentifrice, Test Stannous Fluoride Dentifrice | Phase IV | Gingivitis | Active Not Recruiting | Assessing Gingivitis and Plaque From a Marketed Toothpaste | Aug 28, 2025 | ― |
| 0.76% Sodium Monofluorophosphate Dentifrice, 0.454% Stannous Fluoride Dentifrice | Phase I | Gingivitis | Active Not Recruiting | Evaluating Gingivitis and Systemic Biomarkers | Apr 30, 2025 | ― |
| Sodium Monofluorophosphate Dentifrice, Stannous Fluoride Dentifrice, Sodium Fluoride Dentifrice | Phase II | Gingivitis | Completed | Assessing Gingivitis of 3 Different Dentifrices Compared to a Negative Control. | Mar 19, 2025 | ― |
| 0 Ppm F, 250 Ppm F As Mfp, 1100 Ppm As Mfp, 2800 Ppm F As Mfp | Phase I | Caries | Completed | Salivary Fluoride Clearance | Dec 11, 2024 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Procter & Gamble Company (CH:PG) have in its pipeline
Procter & Gamble CH:PG is currently developing the following drugs: Stannous Fluoride Dentifrice, Sodium Fluoride Dentifrice, Electric Toothbrush, Cetylpyridinium Chloride (Cpc), Manual Toothbrush, Sodium Monofluorophosphate Dentifrice, Stannous Fluoride Dentifrice, Test Stannous Fluoride Dentifrice, 0.76% Sodium Monofluorophosphate Dentifrice, 0.454% Stannous Fluoride Dentifrice, Sodium Monofluorophosphate Dentifrice, Stannous Fluoride Dentifrice, Sodium Fluoride Dentifrice, 0 Ppm F, 250 Ppm F As Mfp, 1100 Ppm As Mfp, 2800 Ppm F As Mfp. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
